- Home
- OLP vs MLYS Comparison
OLP vs MLYS Comparison
Compare OLP & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLP
- MLYS
- Stock Information
- Founded
- OLP 1982
- MLYS 2019
- Country
- OLP United States
- MLYS United States
- Employees
- OLP N/A
- MLYS N/A
- Industry
- OLP Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- OLP Real Estate
- MLYS Health Care
- Exchange
- OLP Nasdaq
- MLYS Nasdaq
- Market Cap
- OLP N/A
- MLYS 634.6M
- IPO Year
- OLP N/A
- MLYS 2023
- Fundamental
- Price
- OLP $25.76
- MLYS $9.24
- Analyst Decision
- OLP Strong Buy
- MLYS Strong Buy
- Analyst Count
- OLP 1
- MLYS 2
- Target Price
- OLP $28.00
- MLYS $30.00
- AVG Volume (30 Days)
- OLP 65.7K
- MLYS 259.6K
- Earning Date
- OLP 03-04-2025
- MLYS 11-11-2024
- Dividend Yield
- OLP 7.03%
- MLYS N/A
- EPS Growth
- OLP 51.11
- MLYS N/A
- EPS
- OLP 1.63
- MLYS N/A
- Revenue
- OLP $89,142,000.00
- MLYS N/A
- Revenue This Year
- OLP N/A
- MLYS N/A
- Revenue Next Year
- OLP $4.71
- MLYS N/A
- P/E Ratio
- OLP $15.81
- MLYS N/A
- Revenue Growth
- OLP N/A
- MLYS N/A
- 52 Week Low
- OLP $19.25
- MLYS $8.28
- 52 Week High
- OLP $30.45
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- OLP 37.32
- MLYS 32.12
- Support Level
- OLP $24.82
- MLYS $8.60
- Resistance Level
- OLP $27.64
- MLYS $9.97
- Average True Range (ATR)
- OLP 0.60
- MLYS 0.88
- MACD
- OLP -0.04
- MLYS -0.31
- Stochastic Oscillator
- OLP 33.33
- MLYS 13.25
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.